Stocks and Investing
Stocks and Investing
Wed, November 15, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Raghuram Selvaraju Reiterated (BTAI) at Strong Buy and Held Target at $11 on, Nov 15th, 2023
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy and Held Target at $11 on, Nov 15th, 2023.
Raghuram has made no other calls on BTAI in the last 4 months.
There are 5 other peers that have a rating on BTAI. Out of the 5 peers that are also analyzing BTAI, 4 agree with Raghuram's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Robyn Karnauskas of "Truist Securities" Downgraded from Strong Buy to Hold on, Thursday, October 5th, 2023
- Graig Suvannavejh of "Mizuho" Reiterated at Hold and Held Target at $4 on, Wednesday, August 23rd, 2023
- Corinne Jenkins of "Goldman Sachs" Maintained at Hold with Decreased Target to $4 on, Tuesday, August 15th, 2023
- Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold on, Monday, July 17th, 2023
This is the rating of the analyst that currently disagrees with Raghuram
- Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $20 on, Tuesday, August 15th, 2023
Contributing Sources